UY30225A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
UY30225A1
UY30225A1 UY30225A UY30225A UY30225A1 UY 30225 A1 UY30225 A1 UY 30225A1 UY 30225 A UY30225 A UY 30225A UY 30225 A UY30225 A UY 30225A UY 30225 A1 UY30225 A1 UY 30225A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
spray drying
drying methods
pharmaceutical
compositions
Prior art date
Application number
UY30225A
Other languages
English (en)
Inventor
Gaspar Felipe
Jeffrey P Katstra
Kevin John Bittorf
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UY30225A1 publication Critical patent/UY30225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describen métodos de secado por rociado.
UY30225A 2006-03-20 2007-03-20 Composiciones farmacéuticas UY30225A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78427506P 2006-03-20 2006-03-20
US87169206P 2006-12-22 2006-12-22

Publications (1)

Publication Number Publication Date
UY30225A1 true UY30225A1 (es) 2007-10-31

Family

ID=38523222

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30225A UY30225A1 (es) 2006-03-20 2007-03-20 Composiciones farmacéuticas

Country Status (22)

Country Link
US (3) US20070218012A1 (es)
EP (1) EP2001497A4 (es)
JP (2) JP2009530416A (es)
KR (2) KR20090025187A (es)
CN (1) CN103272234A (es)
AR (1) AR063468A1 (es)
AU (2) AU2007226984B2 (es)
BR (1) BRPI0708957A2 (es)
CA (1) CA2646335A1 (es)
EA (1) EA018811B1 (es)
EC (1) ECSP088759A (es)
GE (1) GEP20125378B (es)
IL (1) IL194176A (es)
MX (1) MX2008011976A (es)
NO (1) NO20084334L (es)
NZ (1) NZ571934A (es)
PE (1) PE20080170A1 (es)
RS (1) RS20090406A (es)
SG (1) SG170087A1 (es)
TW (2) TW201414469A (es)
UY (1) UY30225A1 (es)
WO (1) WO2007109605A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
EP1993994A2 (en) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterated hepatitis c protease inhibitors
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
HUE055205T2 (hu) 2006-04-07 2021-11-29 Vertex Pharma ATP-kötõ kazetta transzporterek modulátorainak elõállítása
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
SI2114924T1 (sl) 2007-02-27 2012-06-29 Vertex Pharma Ko-kristali in farmacevtski sestavki, ki jih vsebujejo
NZ579295A (en) 2007-02-27 2012-03-30 Vertex Pharma Inhibitors of serine proteases
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
MX2010010214A (es) * 2008-03-20 2010-12-21 Virun Inc Derivados de vitamina e y sus usos.
PL2268160T3 (pl) * 2008-03-20 2013-05-31 Virun Inc Emulsje zawierające pochodną PEG tokoferolu
JP2012517478A (ja) 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2010253578B2 (en) 2009-05-27 2014-01-30 Samyang Biopharmaceuticals Corporation A poorly soluble drug containing microsphere with improved bioavailability and method of preparing the same
JP2013503166A (ja) * 2009-08-25 2013-01-31 カーディオカイン・バイオファーマ・エルエルシー 不溶性剤を送達するための組成物
CN102844030A (zh) 2010-01-29 2012-12-26 沃泰克斯药物股份有限公司 用于治疗丙型肝炎病毒感染的疗法
CN103037708B (zh) * 2010-03-23 2015-05-20 维尔恩公司 含有蔗糖脂肪酸酯的纳米乳液
RU2711481C2 (ru) * 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
US20140308242A1 (en) 2010-10-21 2014-10-16 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
WO2013014665A1 (en) 2011-07-28 2013-01-31 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
WO2013089479A1 (ko) * 2011-12-15 2013-06-20 주식회사 삼양바이오팜 세레콕시브 함유 고체분산체 및 그 제조방법
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
US10874122B2 (en) 2012-02-10 2020-12-29 Virun, Inc. Beverage compositions containing non-polar compounds
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014015217A1 (en) 2012-07-19 2014-01-23 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
US9713594B2 (en) 2012-09-11 2017-07-25 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
JP6192244B2 (ja) 2013-01-22 2017-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改良されたバイオアベイラビリティを有する薬学的組成物
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
KR102601617B1 (ko) * 2013-11-22 2023-11-10 머크 샤프 앤드 돔 엘엘씨 비-뉴클레오시드 역전사 효소 억제제의 조성물
KR20150112416A (ko) * 2014-03-28 2015-10-07 주식회사 일화 세레콕시브 고체분산체 및 그 제조방법
PT107568B (pt) * 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
WO2016090240A1 (en) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
JPWO2018159852A1 (ja) * 2017-03-03 2019-12-26 三栄源エフ・エフ・アイ株式会社 クルクミン含有製剤
CN110958880B (zh) * 2017-05-30 2023-08-08 东莞东阳光太景医药研发有限责任公司 固体分散制剂
CA3071115C (en) 2017-08-04 2022-06-21 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10155234B1 (en) * 2017-08-04 2018-12-18 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10486173B2 (en) 2017-08-04 2019-11-26 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10569244B2 (en) 2018-04-28 2020-02-25 ZoomEssence, Inc. Low temperature spray drying of carrier-free compositions
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
JP2023534737A (ja) 2020-07-24 2023-08-10 ロンザ・ベンド・インコーポレーテッド 酢酸を含むａｐｉの過飽和溶液の噴霧乾燥
JP2023544998A (ja) 2020-10-02 2023-10-26 ロンザ・ベンド・インコーポレーテッド 塩基性薬物の噴霧乾燥における加工助剤としての酢酸
WO2023158616A1 (en) * 2022-02-18 2023-08-24 Viking Therapeutics, Inc. ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0570636A (ja) * 1991-09-17 1993-03-23 Sumitomo Bakelite Co Ltd 熱可塑性樹脂組成物
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
CA2516016C (en) * 2003-03-05 2012-05-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
US20060089385A1 (en) * 2004-06-08 2006-04-27 Yong Cui Pharmaceutical compositions
RS60205B1 (sr) * 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida

Also Published As

Publication number Publication date
IL194176A0 (en) 2011-08-01
US20070218012A1 (en) 2007-09-20
US20090247468A1 (en) 2009-10-01
IL194176A (en) 2013-10-31
TW201414469A (zh) 2014-04-16
AU2007226984A1 (en) 2007-09-27
TWI428125B (zh) 2014-03-01
US20140183768A1 (en) 2014-07-03
CA2646335A1 (en) 2007-09-27
CN103272234A (zh) 2013-09-04
PE20080170A1 (es) 2008-03-10
MX2008011976A (es) 2009-04-07
TW200806280A (en) 2008-02-01
BRPI0708957A2 (pt) 2011-06-28
NO20084334L (no) 2008-11-27
JP2009530416A (ja) 2009-08-27
AU2007226984B2 (en) 2013-02-21
KR20090025187A (ko) 2009-03-10
EA200802008A1 (ru) 2009-04-28
RS20090406A (en) 2010-12-31
SG170087A1 (en) 2011-04-29
AR063468A1 (es) 2009-01-28
ECSP088759A (es) 2008-10-31
EA018811B1 (ru) 2013-10-30
KR20140107691A (ko) 2014-09-04
EP2001497A4 (en) 2012-11-07
GEP20125378B (en) 2012-01-10
NZ571934A (en) 2012-05-25
JP2014037435A (ja) 2014-02-27
AU2013205948A1 (en) 2013-06-06
WO2007109605A3 (en) 2008-01-03
EP2001497A2 (en) 2008-12-17
US8853152B2 (en) 2014-10-07
WO2007109605A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
ECSP088759A (es) Composiciones farmacéuticas
DK2228086T3 (da) Forstøver
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0719499A2 (pt) Composições de poliolefina
RU2398586C3 (ru) Фармацевтическая композиция
DK2079456T3 (da) Farmaceutiske cyclosporinsammensætninger
BRPI0719398A2 (pt) Composição farmacêutica.
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0814745A2 (pt) Composição de produto.
RU2493831C3 (ru) Фармацевтические композиции
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DE602007013051D1 (de) Sprühvorrichtung
BRPI0719275A2 (pt) Composições de carbamatos de fenil-alquil-amino
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
BRPI0716458A2 (pt) Composição de vulcanizado
DE502006006590D1 (de) Biozide zusammensetzungen
BRPI0813867A2 (pt) Composições compreendendo inibidores e hidrolase de triptofano.
BRPI0715173A2 (pt) Composições de perfume
BRPI0816995A2 (pt) Composições de ciclosporina
BRPI0718141A2 (pt) Composições de frangrâncias
BRPI0820198A2 (pt) composições farmacêuticas
ITMI20061291A1 (it) Composizioni (per) fluoroelastomeriche
ATE452628T1 (de) Anthelminthische zusammensetzung